Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 45
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Biol Pharm Bull ; 45(7): 881-887, 2022 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-35474184

RESUMEN

To identify patients at a high risk for primary and secondary osteoporotic fractures using fracture risk assessments performed using the current method and the proposed method, in an acute care hospital and to identify departments where high-risk patients are admitted. This retrospective study included patients aged 40-90 years who were hospitalized at Fujita Health University Hospital. We collated the clinical data and prescriptions of all study participants. We also gathered data pertaining to risk factors according to Fracture Risk Assessment Tool (FRAX). Of the 1595 patients, the mean number of major osteoporotic fracture risk predicted using FRAX was 11.73%. The department of rheumatology showed the highest fracture risk (18.55 ± 16.81) and had the highest number of patients on medications that resulted in reduced bone mineral density (1.07 ± 0.98 medication). Based on the FRAX, the proportion of patients in the high-risk group in this department was significantly higher compared with those in the remaining departments with respect to glucocorticoid administration, rheumatoid arthritis, and secondary osteoporosis. However, the departments included in the high-risk group were not necessarily the same as the departments included in the top group, based on the administered medications. FRAX score is calculated based on various risk factors; however, only glucocorticoid corresponds to medications. We should focus on medication prescription patterns in addition to FRAX to improve fracture risk assessment in hospital-wide surveillance. Therefore, we recommend the use of FRAX along with the prescribed medications to identify departments that admit high-risk patients.


Asunto(s)
Densidad Ósea , Fracturas Osteoporóticas , Glucocorticoides , Hospitales , Humanos , Fracturas Osteoporóticas/epidemiología , Fracturas Osteoporóticas/etiología , Fracturas Osteoporóticas/prevención & control , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo
2.
J Pharmacol Exp Ther ; 368(2): 246-254, 2019 02.
Artículo en Inglés | MEDLINE | ID: mdl-30523061

RESUMEN

Activation of transient receptor potential melastatin 2 (TRPM2), an oxidative stress-sensitive Ca2+-permeable channel, contributes to the aggravation of cerebral ischemia-reperfusion (CIR) injury. Recent studies indicated that treatment with the antidepressant duloxetine for 24 hours (long term) attenuates TRPM2 activation in response to oxidative stress in neuronal cells. To examine the direct effects of antidepressants on TRPM2 activation, we examined their short-term (0-30 minutes) treatment effects on H2O2-induced TRPM2 activation in TRPM2-expressing human embryonic kidney 293 cells using the Ca2+ indicator fura-2. Duloxetine exerted the strongest inhibitory effects on TRPM2 activation among the seven antidepressants tested. These inhibitory effects appeared to be due to the inhibition of H2O2-induced TRPM2 activation via an open-channel blocking-like mechanism, because duloxetine reduced the sustained phase but not the initial phase of increases in intracellular Ca2+ concentrations. In a whole-cell patch-clamp study, duloxetine reduced the TRPM2-mediated inward current during the channel opening state. We also examined the effects of duloxetine in a mouse model of CIR injury. The administration of duloxetine to wild-type mice attenuated CIR injury, similar to that in Trpm2 knockout (KO) mice. The administration of duloxetine did not reduce CIR injury further in Trpm2 KO mice, suggesting that it exerts neuroprotective effects against CIR injury by inhibiting TRPM2 activation. Regarding drug repositioning, duloxetine may be a useful drug in reperfusion therapy for ischemic stroke because it has already been used clinically in therapeutics for several disorders, including depression.


Asunto(s)
Isquemia Encefálica/metabolismo , Clorhidrato de Duloxetina/uso terapéutico , Fármacos Neuroprotectores/uso terapéutico , Daño por Reperfusión/metabolismo , Canales Catiónicos TRPM/antagonistas & inhibidores , Canales Catiónicos TRPM/metabolismo , Animales , Antidepresivos/farmacología , Antidepresivos/uso terapéutico , Isquemia Encefálica/prevención & control , Relación Dosis-Respuesta a Droga , Clorhidrato de Duloxetina/farmacología , Células HEK293 , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Fármacos Neuroprotectores/farmacología , Daño por Reperfusión/prevención & control
3.
Int J Mol Sci ; 19(3)2018 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-29494506

RESUMEN

We have previously demonstrated that acacia polyphenol (AP) exerts strong anti-obesity, anti-diabetic, and anti-atopic dermatitis effects. In the present study, we investigated the anti-hypertensive effects of AP. Spontaneously hypertensive rats (SHR) with hypertension and control Wistar Kyoto rats (WKY) were used. WKY and SHR were fed AP-containing food or AP-free food (control group) ad libitum for 4 weeks, and their blood pressures were measured. After AP administration, both systolic and diastolic blood pressures were significantly lower in the SHR group than in the control group. There were no differences in the systolic or diastolic blood pressure of WKY between the AP group and the control group. Angiotensin-converting enzyme (ACE) activity, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase expression, and superoxide dismutase (SOD) activity in SHR kidneys were not altered by AP administration. Blood SOD activity in SHR was significantly higher in the AP group than in the control group. AP exerts anti-hypertensive effects on hypertension but has almost no effect on normal blood pressure. The anti-hypertensive effects of AP may be related to the anti-oxidative effects of increased blood SOD activity.


Asunto(s)
Acacia/química , Antihipertensivos/farmacología , Hipertensión/metabolismo , Hipertensión/fisiopatología , Extractos Vegetales/farmacología , Polifenoles/farmacología , Animales , Antihipertensivos/química , Presión Sanguínea/efectos de los fármacos , Peso Corporal , Modelos Animales de Enfermedad , Activación Enzimática/efectos de los fármacos , Regulación de la Expresión Génica/efectos de los fármacos , Frecuencia Cardíaca , Hipertensión/tratamiento farmacológico , Riñón/efectos de los fármacos , Riñón/enzimología , Riñón/metabolismo , Masculino , NADPH Oxidasas/genética , NADPH Oxidasas/metabolismo , Estrés Oxidativo/efectos de los fármacos , Peptidil-Dipeptidasa A/metabolismo , Extractos Vegetales/química , Polifenoles/química , Ratas , Ratas Endogámicas SHR , Superóxido Dismutasa/sangre , Superóxido Dismutasa/metabolismo
4.
J Pharmacol Sci ; 134(1): 68-74, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-28532624

RESUMEN

PURPOSE: TRPM2 is a Ca2+-permeable channel that is activated by H2O2. TRPM2-mediated Ca2+ signaling has been implicated in the aggravation of inflammatory diseases. Therefore, the development of TRPM2 inhibitors to prevent the aggravation of these diseases is expected. We recently reported that some Tyrphostin AG-related compounds inhibited the H2O2-induced activation of TRPM2 by scavenging the intracellular hydroxyl radical. In the present study, we examined the effects of AG-related compounds on H2O2-induced cellular responses in human monocytic U937 cells, which functionally express TRPM2. METHODS: The effects of AG-related compounds on H2O2-induced changes in intracellular Ca2+ concentrations, extracellular signal-regulated kinase (ERK) activation, and CXCL8 secretion were assessed using U937 cells. RESULTS: Ca2+ influxes via TRPM2 in response to H2O2 were blocked by AG-related compounds. AG-related compounds also inhibited the H2O2-induced activation of ERK, and subsequent secretion of CXCL8 mediated by TRPM2-dependent and -independent mechanisms. CONCLUSION: Our results show that AG-related compounds inhibit H2O2-induced CXCL8 secretion following ERK activation, which is mediated by TRPM2-dependent and -independent mechanisms in U937 cells. We previously reported that AG-related compounds blocked H2O2-induced TRPM2 activation by scavenging the hydroxyl radical. The inhibitory effects of AG-related compounds on TRPM2-independent responses may be due to scavenging of the hydroxyl radical.


Asunto(s)
Clusterina/metabolismo , Peróxido de Hidrógeno/farmacología , Interleucina-8/metabolismo , Canales Catiónicos TRPM/metabolismo , Tirfostinos/farmacología , Calcio/metabolismo , Activación Enzimática , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Humanos , Peróxido de Hidrógeno/metabolismo , L-Lactato Deshidrogenasa/metabolismo , Estrés Oxidativo , Canales Catiónicos TRPM/química , Tirfostinos/química , Células U937
5.
Biol Pharm Bull ; 38(5): 740-5, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25740003

RESUMEN

Comparative studies of the potency of long- and short-acting erythropoiesis-stimulating agents (L-ESAs and S-ESAs) on erythropoietic activity in patients with chronic kidney disease without dialysis have not been performed, although L-ESAs are used in many countries. We performed a retrospective analysis of non-dialysis (ND) patients who had received L-ESA or S-ESA. More days were needed for the S-ESA-treated group (368 d) to reach the haemoglobin (Hb) reference range than for the L-ESA-treated group (126 d). Therefore, we investigated risk factors that influence the period until the Hb level reaches the reference range. Patients were classified into two groups by the period until the Hb level was stabilised within the reference range: the short- and long-term group. Two risk factors for delayed Hb stabilisation were identified: age ≥60 years; and administration of an S-ESA for initial treatment. These findings suggest that the Hb level should be carefully monitored during ESA therapy in elderly ND patients, and that the ESA dose should be increased or L-ESA therapy should be utilised to treat renal anaemia.


Asunto(s)
Anemia/prevención & control , Eritropoyesis/efectos de los fármacos , Eritropoyetina/sangre , Hematínicos/uso terapéutico , Hemoglobinas/metabolismo , Insuficiencia Renal Crónica/complicaciones , Factores de Edad , Anciano , Anciano de 80 o más Años , Anemia/sangre , Femenino , Hematínicos/farmacología , Humanos , Inmunoterapia Adoptiva , Masculino , Persona de Mediana Edad , Diálisis Renal , Insuficiencia Renal Crónica/sangre , Estudios Retrospectivos , Factores de Tiempo
6.
Biol Pharm Bull ; 37(2): 298-305, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24270587

RESUMEN

We had previously revealed that drug metabolism, as well as the expression level of hepatic CYP3A, a drug-metabolizing enzyme, increase 12 weeks after gastrectomy in mice. In this study, we elucidated the mechanism of the increased CYP3A expression. The levels of lithocholic acid (LCA)-producing bacteria (Bacteroides fragilis) and LCA in the colon did not show a significant increase up to 4 weeks after gastrectomy compared to the sham operation group. In contrast, at 12 and 24 weeks post-gastrectomy, the levels of Bacteroides fragilis and LCA were significantly higher in the gastrectomy group than in the sham operation group. At 12 and 24 weeks after gastrectomy, the hepatic nuclear translocation of pregnane X receptor (PXR) had also increased. The hepatic CYP3A11 mRNA expression and nuclear translocation of PXR after intraperitoneal administration of LCA to normal mice was significantly higher than those of the control group. The intraperitoneal administration of taurolithocholic acid (TLCA), a taurine conjugate of LCA, caused no change in the expression level of CYP3A11. We suggest that the increase in the expression level of CYP3A after gastrectomy is caused by an increase in the nuclear translocation of PXR, which is triggered by an increase in LCA-producing bacteria.


Asunto(s)
Bacteroides fragilis/metabolismo , Colon/microbiología , Citocromo P-450 CYP3A/metabolismo , Enterobacteriaceae/metabolismo , Gastrectomía , Ácido Litocólico/metabolismo , Hígado/metabolismo , Animales , Transporte Biológico , Colon/metabolismo , Citocromo P-450 CYP3A/genética , Inactivación Metabólica , Masculino , Proteínas de la Membrana/genética , Proteínas de la Membrana/metabolismo , Ratones , Ratones Endogámicos ICR , Receptor X de Pregnano , ARN Mensajero/metabolismo , Receptores de Esteroides/metabolismo
7.
Biol Pharm Bull ; 36(4): 649-57, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23358370

RESUMEN

It has been recently reported that the consumption of a high-fat diet during pregnancy exerts various effects on fetuses and newborn mice. The purpose of this study was to determine the effects of a high-fat diet during pregnancy on the expression of cytochrome P450 (CYP) in the livers of offspring. Mouse dams were fed a high-fat diet during pregnancy from the time of conception. After their birth, the newborn mice were fed a normal diet until 12 weeks of age. In the livers of the infant male mice that consumed a high-fat diet, the protein expression of CYP3A and CYP2C was decreased, and the protein expression of CYP1A and CYP2E was increased at 6 and 12 weeks of age. However, almost no changes were observed in the CYP proteins at 6 and 12 weeks of age in the livers of the infant female mice that consumed a high-fat diet. The amount of pregnane X receptor (PXR) translocated into the nucleus was reduced in the livers of infant male mice that consumed a high-fat diet. However, there was neither an increase in tumor necrosis factor-α or interleukin-1ß nor a decrease in lithocholic acid. These data suggested that CYP3A and CYP2C might decrease as a result of the decrease in the amount of nuclear PXR in infant male mice that consumed a high-fat diet. The results of this study suggested that the consumption of a high-fat diet by pregnant mothers may be one explanation for individual differences in pharmacokinetics.


Asunto(s)
Sistema Enzimático del Citocromo P-450/metabolismo , Dieta Alta en Grasa , Hígado/metabolismo , Efectos Tardíos de la Exposición Prenatal , Animales , Animales Recién Nacidos , Bacteroides fragilis/genética , Bacteroides fragilis/aislamiento & purificación , ADN Bacteriano/análisis , Heces/microbiología , Femenino , Interleucina-1beta/genética , Masculino , Ratones , Ratones Endogámicos ICR , Embarazo , Receptor X de Pregnano , Receptores de Esteroides/metabolismo , Triglicéridos/metabolismo , Factor de Necrosis Tumoral alfa/genética
8.
Biol Pharm Bull ; 36(4): 624-34, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23370405

RESUMEN

Changes in the expression level and activity of cytochrome P450 (CYP) in the liver are caused by various factors and affect the pharmacokinetics of drugs. The purpose of this study was to determine whether the expression of CYP3A is affected by a high-fat diet. In addition, we examined whether the type of diet given to mice could produce changes in the expression level and activity of CYP3A. Mice were fed a purified diet containing 10 kcal% lard (control group) or 60 kcal% lard (HF group) or regular mouse chow containing 13 kcal% of fat (MF group) for 4 weeks. No significant differences were observed in the hepatic CYP3A protein expression level between the HF group and the control group. The CYP3A protein expression in the MF group was significantly higher than that observed in the control group. In the MF group, the area under the curve (AUC) of intraperitoneally administered triazolam was lower. Because lithocholic acid (LCA) is known to increase hepatic CYP3A expression, the levels of Clostridium sordellii and LCA in the feces were measured. In the MF group, the levels of Clostridium sordellii and LCA were higher. It has been demonstrated that a high-fat diet does not cause any changes in hepatic CYP3A expression. In addition, the different diets caused alterations in the enteric environment, which triggered changes in CYP3A expression. Therefore, it is necessary to carefully consider the type of feed while performing animal experiments to evaluate the pharmacokinetics of drugs.


Asunto(s)
Sistema Enzimático del Citocromo P-450/metabolismo , Dieta Alta en Grasa , Hígado/metabolismo , Tejido Adiposo Blanco/crecimiento & desarrollo , Animales , Glucemia/análisis , Peso Corporal , Colesterol/sangre , Citocromo P-450 CYP3A/genética , Ácidos Grasos no Esterificados/sangre , Heces/química , Ácido Litocólico/metabolismo , Hígado/crecimiento & desarrollo , Masculino , Proteínas de la Membrana/genética , Ratones , Ratones Endogámicos ICR , Microsomas/metabolismo , Tamaño de los Órganos , ARN Mensajero/metabolismo , Triazolam/farmacocinética , Triglicéridos/sangre
9.
Chem Pharm Bull (Tokyo) ; 61(8): 846-52, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23902867

RESUMEN

Compound 1 (IT-M-07000) was previously reported as a candidate prodrug of Am80 (Tamibarotene; used to treat acute promyelocytic leukemia), and shown to be efficiently metabolized to Am80 via ß-oxidation. Here, we describe in detail the synthesis of 1, together with another tetradeuterated candidate prodrug, IT-YA-00616 (2), as well as two congeners, and several metabolic intermediates of 1 previously detected in mouse plasma.


Asunto(s)
Benzoatos/metabolismo , Fenilpropionatos/síntesis química , Profármacos/síntesis química , Receptores de Ácido Retinoico/agonistas , Tetrahidronaftalenos/síntesis química , Tetrahidronaftalenos/metabolismo , Humanos , Leucemia Promielocítica Aguda/tratamiento farmacológico , Oxidación-Reducción , Fenilpropionatos/metabolismo , Profármacos/metabolismo
10.
Bioorg Med Chem Lett ; 22(24): 7602-4, 2012 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-23103098

RESUMEN

Neuropathic pain is a chronic pain condition resulting from neuronal damage, and is usually treated with pregabalin or gabapentin, which are structurally related to γ-aminobutyric acid (GABA) and are originally developed as anticonvulsant drugs. Here, we report the synthesis and pharmacology of (R)- and (S)-4-amino-3-(trimethylsilyl)methylbutanoic acids (1a and 1b), which showed analgesic activity as potent as that of pregabalin in the Chung spinal nerve ligation model. However, unlike pregabalin, 1a and 1b do not have antiepileptic effects, and they are therefore promising candidates for selective therapeutic agents to treat neuropathic pain without central nervous system-related side effects.


Asunto(s)
Analgésicos/uso terapéutico , Anticonvulsivantes/uso terapéutico , Butiratos/uso terapéutico , Enfermedades del Sistema Nervioso Central/tratamiento farmacológico , Neuralgia/tratamiento farmacológico , Compuestos de Trimetilsililo/uso terapéutico , Analgésicos/síntesis química , Analgésicos/química , Animales , Anticonvulsivantes/síntesis química , Anticonvulsivantes/química , Butiratos/síntesis química , Butiratos/química , Relación Dosis-Respuesta a Droga , Ensayos de Selección de Medicamentos Antitumorales , Estructura Molecular , Ratas , Estereoisomerismo , Compuestos de Trimetilsililo/síntesis química , Compuestos de Trimetilsililo/química
11.
Biol Pharm Bull ; 35(2): 231-8, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22293354

RESUMEN

The purpose of this study was to clarify the anti-fatigue effect of Conclevan, which is mainly composed of liver hydrolysate, via a forced swimming test using mice. Conclevan was administered to mice for 6 weeks, and a forced swimming test was conducted to measure swimming time. After six weeks, the blood ammonia and glutamine concentrations were measured. In the Conclevan administration group, swimming time increased significantly compared to the swimming control group. In the swimming control group, an increase in blood ammonia and a decrease in blood glutamine were observed, relative to the non-swimming control group. In the Conclevan administration group, the increased blood ammonia and decreased blood glutamine induced by swimming were significantly reduced, compared to the swimming control group. The mRNA expression levels of the hepatic enzymes of the urea cycle (carbamoyl-phosphate synthetase, argininosuccinate synthetase, and arginase) and glutamine synthesis (glutamate dehydrogenase and glutamine synthetase) were significantly increased in the Conclevan administration group, compared to the swimming control group. The results of this study demonstrated the anti-fatigue effects of Conclevan. This product may inhibit an increase in the fatigue-inducing ammonia concentration in the blood by increasing the expression of hepatic enzymes, which convert ammonia to urea, leading to increased swimming time. In addition, Conclevan may prolong swimming time by increasing the hepatic synthesis of glutamine, which is an important amino acid for supplying energy in muscles.


Asunto(s)
Fatiga/prevención & control , Resistencia Física/efectos de los fármacos , Extractos de Tejidos/farmacología , Complejo Vitamínico B/farmacología , Amoníaco/sangre , Animales , Glucemia/análisis , Corticosterona/sangre , Fatiga/sangre , Glutamina/sangre , Ácido Láctico/sangre , Hígado/efectos de los fármacos , Hígado/metabolismo , Masculino , Ratones , Riboflavina/farmacología , Natación , Tiamina/farmacología , Urea/metabolismo , Vitamina B 12/farmacología , Vitamina B 6/farmacología
12.
Biol Pharm Bull ; 35(6): 957-62, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22687538

RESUMEN

Aquaporin (AQP) 3, which is predominantly expressed in the colon, is considered to play an important role in regulating the fecal water content in the colon. In this study, the role of AQP3 in the colon was examined using HgCl(2) and CuSO(4), which are known to inhibit AQP3 function. The fecal water content was measured up to 1 h after the rectal administration of HgCl(2) or CuSO(4) to rats. The results showed that the fecal water content in the HgCl(2) administration group increased significantly to approximately 4 times that in the control group, and severe diarrhea was observed. However, no changes were observed in the mRNA expression level of the osmoregulatory genes (sodium myo-inositol transporter and taurine transporter) and the level and distribution of AQP3 protein expression, as determined 1 h after the administration of HgCl(2). Comparable results were observed in the CuSO(4) administration group. The results of this study indicated that the inhibition of AQP3 function in the colon caused diarrhea. Therefore, it has been revealed that the fecal water content in the colon is controlled by the transport of water from the luminal side to the vascular side, which is mediated by AQP3. Our findings suggest that a drug that modulates the function or expression of AQP3 in the colon may represent a new target for the development of laxatives.


Asunto(s)
Acuaporina 3/fisiología , Colon/fisiología , Diarrea/metabolismo , Heces/química , Agua/metabolismo , Animales , Acuaporina 3/antagonistas & inhibidores , Colon/efectos de los fármacos , Sulfato de Cobre/farmacología , Diarrea/inducido químicamente , Diarrea/fisiopatología , Masculino , Glicoproteínas de Membrana/genética , Proteínas de Transporte de Membrana/genética , Cloruro de Mercurio/farmacología , ARN Mensajero/metabolismo , Ratas , Ratas Wistar , Simportadores/genética
13.
Artículo en Inglés | MEDLINE | ID: mdl-22315629

RESUMEN

We examined the inhibitory effect of polyphenol-rich aqueous extract from the bark of Acacia mearnsii (PrA) on itching associated with atopic dermatitis (AD). HR-1 mice were fed a normal diet, special diet (AD group), or special diet containing 3% PrA (PrA group) for 6 weeks. In the AD group, itching frequency and transepidermal water loss increased compared to the control group. In the PrA group, an improvement in atopic dermatitis symptoms was observed. Ceramide expression in the skin decreased in the AD group compared to the control group, but no decrease was observed in the PrA group. mRNA expression of ceramidase decreased in the PrA group compared to the AD group. The results of this study have revealed that PrA inhibits itching in atopic dermatitis by preventing the skin from drying. It is considered that the mechanism by which PrA prevents the skin from drying involves the inhibition of increased ceramidase expression associated with atopic dermatitis.

14.
Phytother Res ; 26(1): 91-100, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-21557367

RESUMEN

Obesity is a major cause of metabolic syndrome and is due to an increase in the number and hypertrophy of adipocytes. Accordingly, inhibition of the differentiation and proliferation of adipocytes may be used in the treatment and prevention of metabolic syndrome. This study investigated the effects of 50 commonly used Kampo medicines on the differentiation of 3T3-L1 preadipocytes to search for a drug with an antiobesity effect. Kampo medicines were screened, and the strongest differentiation-inhibitory effect was noted with Orengedokuto. To explore the active ingredients in Orengedokuto, the effects of four crude drug components of Orengedokuto were investigated. It was found that the differentiation-inhibitory effect of Orengedokuto was accounted for by Coptidis rhizome and Phellodendri cortex. Furthermore, berberine, a principal ingredient common to Coptidis rhizome and Phellodendri cortex, showed a differentiation-inhibitory effect. The effect of berberine involves an inhibition of the mRNA and protein expression of peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer binding protein α (C/EBPα). Moreover, berberine inhibited lipid accumulation in adipocytes. These findings suggest that an antiobesity effect could be a new indication for Orengedokuto and that its active ingredient is berberine, with a mechanism involving the inhibition of PPARγ and C/EBPα expression.


Asunto(s)
Adipocitos/efectos de los fármacos , Berberina/uso terapéutico , Diferenciación Celular/efectos de los fármacos , Medicamentos Herbarios Chinos/uso terapéutico , Metabolismo de los Lípidos/efectos de los fármacos , Obesidad/prevención & control , Fitoterapia , Células 3T3-L1 , Adipocitos/fisiología , Animales , Fármacos Antiobesidad/farmacología , Fármacos Antiobesidad/uso terapéutico , Berberina/farmacología , Proteína alfa Potenciadora de Unión a CCAAT/genética , Proteína alfa Potenciadora de Unión a CCAAT/metabolismo , Proliferación Celular/efectos de los fármacos , Coptis/química , Evaluación Preclínica de Medicamentos , Medicamentos Herbarios Chinos/química , Medicamentos Herbarios Chinos/farmacología , Medicina Kampo , Ratones , Obesidad/metabolismo , PPAR gamma/genética , PPAR gamma/metabolismo , Phellodendron/química , Corteza de la Planta , ARN Mensajero/metabolismo , Rizoma
15.
Am J Physiol Gastrointest Liver Physiol ; 301(5): G887-95, 2011 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-21868635

RESUMEN

The purpose of this study was to investigate the role of aquaporin3 (AQP3) in the colon in the laxative effect of bisacodyl. After oral administration of bisacodyl to rats, AQP3, macrophages, cyclooxygenase 2 (COX2), and prostaglandin E(2) (PGE(2)) were examined in the colon. The mechanism by which bisacodyl decreases the expression of AQP3 was examined using HT-29 and Raw264.7 cells. When diarrhea occurred, a significant increase in the expression of PGE(2) and a decrease in AQP3 expression were observed. Immunostaining showed COX2 expression only in macrophages. The PGE(2) concentration increased significantly 30 min after the addition of bisacodyl to Raw264.7 cells. Thirty minutes after PGE(2) addition to HT-29 cells, the AQP3 expression level decreased to 40% of the control. When pretreated with indomethacin, bisacodyl did not induce an increase in the colon PGE(2) level, a decrease in the AQP3 expression level, or diarrhea. The results suggest that bisacodyl may decrease the expression of AQP3 in the colon, which inhibits water transfer from the luminal to the vascular side and leads to a laxative effect. This study also showed that direct activation of colon macrophages by bisacodyl increases the secretion of PGE(2), which acts as a paracrine factor and decreases AQP3 expression in colon mucosal epithelial cells.


Asunto(s)
Acuaporina 3/metabolismo , Bisacodilo/farmacología , Catárticos/farmacología , Colon/metabolismo , Dinoprostona/metabolismo , Macrófagos/metabolismo , Animales , Acuaporina 3/genética , Colon/efectos de los fármacos , Ciclooxigenasa 2/metabolismo , Inhibidores de la Ciclooxigenasa/farmacología , Células Epiteliales/efectos de los fármacos , Células Epiteliales/metabolismo , Indometacina/farmacología , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/metabolismo , Macrófagos/efectos de los fármacos , Masculino , Ratas , Ratas Wistar
16.
Biol Pharm Bull ; 34(2): 238-42, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21415534

RESUMEN

Aquaporin (AQP) 3 plays an important role in regulating faecal water content in the colon. We investigated the role of AQP3 in the colon in the laxative effect of magnesium sulphate (MgSO(4)), a widely used osmotic laxative. Rats were administered MgSO(4), after which faecal water content, the colon mRNA expression levels of sodium myo-inositol transporter (SMIT) and taurine transporter (TauT), the colon protein expression levels of AQP3 were examined. Faecal water content increased over time after MgSO(4) administration, and severe diarrhoea was observed between 4 and 8 h after administration. The mRNA expression levels of SMIT and TauT, which are indicators of variations in osmotic pressure, were highest at 2 h after the administration of MgSO(4) and were still elevated at 8 h after administration when compared to immediately after the administration. The immunostaining analysis showed that AQP3 is a dominant AQP in the rat colon. The protein expression levels of AQP3 in the colon increased over time following the administration of MgSO(4) and at 8 h after administration were approximately 8 times higher than baseline levels. Previously, osmotic laxatives were believed to induce diarrhoea by elevating the osmotic pressure in the intestinal tract. The results of the present study suggest that the laxative effect of MgSO(4) is not simply caused by a change in the osmotic pressure in the intestinal tract, but could be a response to increased expression of AQP3.


Asunto(s)
Acuaporina 3/metabolismo , Colon/efectos de los fármacos , Diarrea/etiología , Laxativos/farmacología , Sulfato de Magnesio/farmacología , Ósmosis/efectos de los fármacos , Animales , Transporte Biológico , Colon/metabolismo , Diarrea/metabolismo , Heces/química , Inositol/metabolismo , Sulfato de Magnesio/efectos adversos , Masculino , Glicoproteínas de Membrana/genética , Glicoproteínas de Membrana/metabolismo , Proteínas de Transporte de Membrana/genética , Proteínas de Transporte de Membrana/metabolismo , Presión Osmótica , ARN Mensajero/metabolismo , Ratas , Ratas Wistar , Sodio/metabolismo , Simportadores/genética , Simportadores/metabolismo , Agua/metabolismo
17.
Xenobiotica ; 41(6): 486-93, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21319957

RESUMEN

In humans, digoxin is mainly eliminated through the kidneys unchanged, and renal clearance represents approximately 70% of the total clearance. In this study, we used the mouse models to examine digoxin pharmacokinetics in polyuria induced by diabetes mellitus and lithium carbonate (Li(2)CO(3)) administration, including mechanistic evaluation of the contribution of glomerular filtration, tubular secretion, and tubular reabsorption. After digoxin administration to streptozotocin (STZ)-induced diabetic mice, digoxin CL/F increased to approximately 2.2 times that in normal mice. After treatment with Li(2)CO(3) (0.2%) for 10 days, the CL/F increased approximately 1.1 times for normal mice and 1.6 times for STZ mice. Creatinine clearance (CLcr) and the renal mRNA expression levels of mdr1a did not differ significantly between the normal, STZ, and Li(2)CO(3)-treated mice. The urine volume of STZ mice was approximately 26 mL/day, 22 times that of normal mice. The urine volume of Li(2)CO(3)-treated mice increased approximately 7.3 times for normal mice and 2.3 times for STZ mice. These results suggest that the therapeutic effect of digoxin may be significantly reduced in the presence of polyuria either induced by diabetes mellitus or manifested as an adverse effect of Li(2)CO(3) in diabetic patients, along with increased urine volume.


Asunto(s)
Antiarrítmicos/farmacocinética , Antidepresivos/farmacología , Diabetes Mellitus Experimental/metabolismo , Digoxina/farmacocinética , Carbonato de Litio/farmacología , Poliuria/metabolismo , Subfamilia B de Transportador de Casetes de Unión a ATP/genética , Subfamilia B de Transportador de Casetes de Unión a ATP/metabolismo , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Animales , Antidepresivos/efectos adversos , Acuaporina 2/metabolismo , Acuaporina 2/orina , Acuaporina 3/metabolismo , Acuaporina 3/orina , Creatinina/metabolismo , Interacciones Farmacológicas , Riñón/efectos de los fármacos , Riñón/metabolismo , Carbonato de Litio/efectos adversos , Masculino , Ratones , Ratones Endogámicos ICR , Modelos Biológicos , Poliuria/inducido químicamente , ARN Mensajero/metabolismo , Estreptozocina
18.
Artículo en Inglés | MEDLINE | ID: mdl-21799697

RESUMEN

Acacia polyphenol (AP) extracted from the bark of the black wattle tree (Acacia meansii) is rich in unique catechin-like flavan-3-ols, such as robinetinidol and fisetinidol. The present study investigated the anti-obesity/anti-diabetic effects of AP using obese diabetic KKAy mice. KKAy mice received either normal diet, high-fat diet or high-fat diet with additional AP for 7 weeks. After the end of administration, body weight, plasma glucose and insulin were measured. Furthermore, mRNA and protein expression of obesity/diabetic suppression-related genes were measured in skeletal muscle, liver and white adipose tissue. As a result, compared to the high-fat diet group, increases in body weight, plasma glucose and insulin were significantly suppressed for AP groups. Furthermore, compared to the high-fat diet group, mRNA expression of energy expenditure-related genes (PPARα, PPARδ, CPT1, ACO and UCP3) was significantly higher for AP groups in skeletal muscle. Protein expressions of CPT1, ACO and UCP3 for AP groups were also significantly higher when compared to the high-fat diet group. Moreover, AP lowered the expression of fat acid synthesis-related genes (SREBP-1c, ACC and FAS) in the liver. AP also increased mRNA expression of adiponectin and decreased expression of TNF-α in white adipose tissue. In conclusion, the anti-obesity actions of AP are considered attributable to increased expression of energy expenditure-related genes in skeletal muscle, and decreased fatty acid synthesis and fat intake in the liver. These results suggest that AP is expected to be a useful plant extract for alleviating metabolic syndrome.

19.
Phytother Res ; 25(6): 897-903, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21110398

RESUMEN

Byakkokaninjinto (BKN) is an herbal medicine used for the relief of diuresis, thirst and dermal pruritus that are associated with diabetes. The effects of BKN on the expression of aquaporins (AQPs) in the kidney, salivary gland and skin were investigated in order to clarify the mechanism of drug action. Seven-week-old KKAy mice were given feed containing 4.5% BKN for 4 weeks. Compared with the control group, BKN administration did not affect the blood glucose and insulin concentration. However, water intake and urine volume were significantly reduced. AQP2 protein expression in the kidney inner medullary was significantly increased after BKN administration. AQP3 mRNA and protein expression in skin tissue was significantly increased after BKN administration. However, BKN administration did not affect AQP5 mRNA expression in the salivary gland. These results suggest that BKN treatment relieves diuresis, thirst, and dermal pruritis by increasing kidney AQP2 expression and skin AQP3 expression.


Asunto(s)
Acuaporina 2/biosíntesis , Acuaporina 3/biosíntesis , Agua Corporal/metabolismo , Medicamentos Herbarios Chinos/farmacología , Riñón/efectos de los fármacos , Extractos Vegetales/farmacología , Piel/efectos de los fármacos , Anemarrhena/química , Animales , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/metabolismo , Diuresis/efectos de los fármacos , Regulación de la Expresión Génica/efectos de los fármacos , Glycyrrhiza/química , Humanos , Riñón/metabolismo , Ratones , Modelos Animales , Oryza/química , Panax/química , Glándulas Salivales/metabolismo , Piel/metabolismo
20.
Nanoscale ; 13(3): 1784-1790, 2021 Jan 28.
Artículo en Inglés | MEDLINE | ID: mdl-33433554

RESUMEN

Plasmon-induced chemical reactions triggered by near-infrared light illumination might enable efficient photo energy conversion. Here, electrochemical oxidative polymerization of a conductive polymer was conducted on plasmonic photoconversion electrodes. The absolute electrochemical potential of the generated holes was estimated from the redox potentials of the monomers. In addition, well-defined plasmonic structures were examined to better understand the relationship between the excited plasmon mode and spatial distribution of reaction active sites. Rod structures with various lengths had distinct spatial distributions of reaction active sites that depended on the higher plasmon modes, as visualized by Raman measurements.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA